PDF icon PDF herunterladen
Open Access
CC BY 4.0 · Journal of Diabetes and Endocrine Practice
DOI: 10.1055/s-0045-1811602
Commentary

Atherosclerotic Cardiovascular Diseases in Type 2 Diabetes in the Middle East and Africa: Insights from the PACT-MEA Study

Salem A. Beshyah 
1   Department of Medicine, Bareen International Hospital, Abu Dhabi, United Arab Emirates
2   Department of Medicine, College of Medicine, Dubai Medical University, Dubai, United Arab Emirates
› Institutsangaben
Funding and Sponsorship None.
› Weitere Informationen
Auch verfügbar aufeRef
  Lizenzen und Reprints
Preview

Abstract

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality among individuals with type 2 diabetes (T2D), particularly in regions with high diabetes prevalence, like the Middle East and Africa (MEA). However, contemporary data on ASCVD burden and management in these regions remain limited. The recent PACT-MEA study evaluated the prevalence of established ASCVD (eASCVD), cardiovascular risk profiles, and treatment practices in patients with T2D across seven countries. Several manuscripts and presentations on aspects of the study were published in several journals and conferences. This commentary consolidates a concise resume of the study. The PACT-MEA study is a multinational, cross-sectional, observational chart review and physician survey conducted across 55 centers in Bahrain, Egypt, Jordan, Kuwait, Qatar, South Africa, and the United Arab Emirates. Data were collected from 3,726 adults with T2D and approximately 400 physicians. The weighted prevalence of eASCVD was 20.9%, with substantial variation by age and country. Nearly all participants have high or very high cardiovascular risk. Only 30 to 37% met individual treatment targets for HbA1c, blood pressure, and low-density lipoprotein cholesterol. Utilization of cardioprotective therapies was suboptimal. No participant achieved all guideline targets. The PACT-MEA and DISCOVER-MEA studies shared some objectives but differed in scope, design, and primary outcomes. The burden of ASCVD and associated risk among patients with T2D in the MEA region is alarmingly high, but comprehensive risk factor control is insufficient. The PACT-MEA study findings underscored an urgent need for targeted regional strategies to improve cardiovascular outcomes.

Keywords

type 2 diabetes - atherosclerotic cardiovascular disease - cardiovascular risk - Middle East - Africa - PACT-MEA - DISCOVER

Compliance with Ethical Principles

No ethical approval is required for a narrative review article type of study.


Data Availability Statement

Not applicable.




Publikationsverlauf

Artikel online veröffentlicht:
05. September 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Standl E, Khunti K, Hansen TB, Schnell O. The global epidemics of diabetes in the 21st century: Current situation and perspectives. Eur J Prev Cardiol 2019; 26 (2_suppl, suppl): 7-14
    CrossrefPubMedSuche in Google Scholar
  • 2 International Diabetes Federation. IDF Diabetes Atlas. 11th ed. 2025. Accessed August 17, 2025 at: https://diabetesatlas.org/resources/idf-diabetes-atlas-2025
  • 3 El-Kebbi IM, Bidikian NH, Hneiny L, Nasrallah MP. Epidemiology of type 2 diabetes in the Middle East and North Africa: challenges and call for action. World J Diabetes 2021; 12 (09) 1401-1425
    CrossrefPubMedSuche in Google Scholar
  • 4 Dal Canto E, Ceriello A, Rydén L. et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol 2019; 26 (2_suppl): 25-32
    CrossrefPubMedSuche in Google Scholar
  • 5 Al Sayed N, Al Waili K, Alawadi F. et al. Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East. Int J Cardiol 2016; 225: 268-283
    CrossrefPubMedSuche in Google Scholar
  • 6 Sabbour H, Almahmeed W, Alawadi F. et al. Emirates consensus recommendations on cardiovascular risk management in type 2 diabetes. Front Endocrinol (Lausanne) 2025; 15: 1395630
    CrossrefPubMedSuche in Google Scholar
  • 7 Sonmez A, Sabbour H, Echtay A. et al. Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: expert recommendations. J Diabetes 2022; 14 (05) 315-333
    CrossrefPubMedSuche in Google Scholar
  • 8 Verma S, Sabbour H, Alamuddin N. et al. A cross-sectional study of the prevalence and clinical management of atherosclerotic cardiovascular diseases in patients with type 2 diabetes across the Middle East and Africa (PACT-MEA): study design and rationale. Diabetes Obes Metab 2023; 25 (06) 1444-1452
    CrossrefPubMedSuche in Google Scholar
  • 9 Verma S, Alamuddin N, Alawadi F. et al. Prevalence of diabetes and cardiovascular risk in the Middle East and Africa: primary results of the PACT-MEA study. Circulation 2023; 147 (16) 1251-1255
    CrossrefPubMedSuche in Google Scholar
  • 10 Hafidh K, Malek R, Al-Rubeaan K. et al. Prevalence and risk factors of vascular complications in type 2 diabetes mellitus: results from discover Middle East and Africa cohort. Front Endocrinol (Lausanne) 2022; 13: 940309
    CrossrefPubMedSuche in Google Scholar
  • 11 Al-Rubeaan K, Alsayed M, Ben-Nakhi A. et al. Characteristics and treatment patterns of patients with type 2 diabetes mellitus in the Middle East and Africa cohort of the DISCOVER study program: a prospective study. Diabetes Ther 2022; 13 (07) 1339-1352
    CrossrefPubMedSuche in Google Scholar
  • 12 Visseren FLJ, Mach F, Smulders YM. et al; ESC National Cardiac Societies, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42 (34) 3227-3337
    CrossrefPubMedSuche in Google Scholar
  • 13 Bashier A, Agrawal A, Dhanwal D. et al. Achievement of guideline targets among people with type 2 diabetes with eASCVD and high risk of ASCVD in the UAE: results of the PACT-MEA-UAE cohort. Diabetes Res Clin Pract 2025; 221: 112030
    CrossrefPubMedSuche in Google Scholar
  • 14 Elhadd T, Beer S, Khalaf S. et al. Prevalence and association of microvascular complications with atherosclerotic cardiovascular disease in people with type 2 diabetes in the Gulf region: results from the PACT-MEA study. J Diabetes Treat 2025; 10: 10146
    Suche in Google Scholar
  • 15 Alawadi F, Samir H, Assaad-Khalil SH. et al. 21-LB: prevalence of atherosclerotic cardiovascular diseases in women with type 2 diabetes across the Middle East and Africa—primary gender analysis of the PACT-MEA study. Diabetes 2023; 72 (01) 21
    CrossrefSuche in Google Scholar
  • 16 Haddad J, Almahmeed W, Salek S. et al. Assessment of age in established atherosclerotic disease or high/very high risk among patients with type 2 diabetes across the Middle East and Africa: the PACT-MEA study. Diabetologia 2023; 66 (SUPPL 1): S496
    Suche in Google Scholar
  • 17 Yadav G, Assaad-Khalil S, Alawadi F. et al. Obesity and ASCVD/ASCVD risk in patients with type 2 diabetes across the Middle East and Africa. Obesity (Silver Spring) 2023; 31 (02) 96
    PubMedSuche in Google Scholar
  • 18 Sabbour H, Alamuddin N, Alawadi F. et al. Dyslipidaemia and its management in patients with type 2 diabetes across the Middle East and Africa: the PACT-MEA study. Eur Heart J 2023; 44 (02) ehad655
    Suche in Google Scholar
  • 19 Al-Dahi WA, Khalaf SH, AlRomaihi DA. et al. GLP-1RA and SGLT2i utilization in people with type 2 diabetes with atherosclerotic cardiovascular disease (ASCVD) or at high risk of ASCVD in the Gulf Region: results from the PACT-MEA studys. Saudi Med J 2025; 46 (02) 163-170
    CrossrefPubMedSuche in Google Scholar
  • 20 Gawish H, Bassyouni A, Toaima D. et al. The use of antidiabetic pharmacotherapy with cardiovascular benefits in type 2 diabetes: highlights from the Egyptian cohort of the PACT-MEA study. Endocr Pract 2024; 30 (12) S14-S15
    CrossrefSuche in Google Scholar
  • 21 Alkandari H, Jayyousi A, Shalaby A. et al. Prevalence of atherosclerotic cardiovascular disease in people with type 2 diabetes in the Gulf Region: results from the PACT-MEA study. Public Health 2025; 242: 21-27
    CrossrefPubMedSuche in Google Scholar
  • 22 Awadi FA, Rashid F, Awada G. et al. Prevalence of cardiovascular risk and atherosclerotic cardiovascular disease in people with type 2 diabetes in the United Arab Emirates: results from the prevalence of atherosclerotic cardiovascular disease in patients with type 2 diabetes across Middle East and African countries (PACT-MEA) study. Diabetes Metab Syndr 2025; 19 (04) 103224
    CrossrefPubMedSuche in Google Scholar
  • 23 Haddad JA, Annabi FOA, Abbasi H. et al. The prevalence of atherosclerotic cardiovascular disease in patients with type 2 diabetes in Jordan: the PACT-MEA study. Diabetes Ther 2025; 16 (05) 899-913
    CrossrefPubMedSuche in Google Scholar
  • 24 Assaad-Khalil S, Bassyouni A, Toaima D. et al. Atherosclerotic cardiovascular disease and its risk factors in type 2 diabetes in Egypt: insights from PACT-MEA study and implications for interventions. Endocrine Abstracts 2024; 99: EP3
    Suche in Google Scholar